236 related articles for article (PubMed ID: 37493887)
21. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
[TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacology of axitinib.
Chen Y; Tortorici MA; Garrett M; Hee B; Klamerus KJ; Pithavala YK
Clin Pharmacokinet; 2013 Sep; 52(9):713-25. PubMed ID: 23677771
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive review on Brigatinib - A wonder drug for targeted cancer therapy in non-small cell lung cancer.
Bedi S; Khan SA; AbuKhader MM; Alam P; Siddiqui NA; Husain A
Saudi Pharm J; 2018 Sep; 26(6):755-763. PubMed ID: 30202213
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
[TBL] [Abstract][Full Text] [Related]
25. Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.
Hohmann N; Bozorgmehr F; Christopoulos P; Mikus G; Blank A; Burhenne J; Thomas M; Haefeli WE
Clin Transl Sci; 2021 Mar; 14(2):487-491. PubMed ID: 33222380
[TBL] [Abstract][Full Text] [Related]
26. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
27. Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer.
Tan W; Yamazaki S; Johnson TR; Wang R; O'Gorman MT; Kirkovsky L; Boutros T; Brega NM; Bello A
Clin Drug Investig; 2017 Apr; 37(4):363-373. PubMed ID: 28035616
[TBL] [Abstract][Full Text] [Related]
28. Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial.
Garcia Campelo MR; Wan Y; Lin HM; Chen T; Shen J; Zhang P; Camidge DR
Lung Cancer; 2023 Nov; 185():107376. PubMed ID: 37722340
[TBL] [Abstract][Full Text] [Related]
29. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
[TBL] [Abstract][Full Text] [Related]
30. Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC.
Ng TL; Narasimhan N; Gupta N; Venkatakrishnan K; Kerstein D; Camidge DR
J Thorac Oncol; 2020 Jul; 15(7):1190-1199. PubMed ID: 32135189
[TBL] [Abstract][Full Text] [Related]
31. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
[TBL] [Abstract][Full Text] [Related]
32. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
33. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Hirota T; Muraki S; Ieiri I
Clin Pharmacokinet; 2019 Apr; 58(4):403-420. PubMed ID: 29915924
[TBL] [Abstract][Full Text] [Related]
34. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Kay S; Walton LJ; Shen J; Popat S; Camidge DR
Curr Med Res Opin; 2022 Sep; 38(9):1587-1593. PubMed ID: 35815801
[TBL] [Abstract][Full Text] [Related]
35. Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.
Spencer SA; Riley AC; Matthew A; Di Pasqua AJ
Ann Pharmacother; 2019 Jun; 53(6):621-626. PubMed ID: 30638036
[TBL] [Abstract][Full Text] [Related]
36. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
[TBL] [Abstract][Full Text] [Related]
37. The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Venkatakrishnan K; Sonnichsen D; Kerstein D; Dorer DJ; Narasimhan N
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):734-741. PubMed ID: 30570839
[TBL] [Abstract][Full Text] [Related]
38. Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC.
Hoy SM
Drugs; 2021 Feb; 81(2):267-275. PubMed ID: 33528789
[TBL] [Abstract][Full Text] [Related]
39. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
[TBL] [Abstract][Full Text] [Related]
40. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
